Market Cap 43.45M
Revenue (ttm) 0.00
Net Income (ttm) -24.59M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 210,800
Avg Vol 229,816
Day's Range N/A - N/A
Shares Out 19.49M
Stochastic %K 77%
Beta 1.63
Analysts Strong Sell
Price Target $11.67

Company Profile

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer's disease, as well as in phase 3 to treat parkinson's disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phas...

Industry: Biotechnology
Sector: Healthcare
Phone: 484 875 3192
Address:
101 Lindenwood Drive, Suite 225, Malvern, United States
ForestFoxes
ForestFoxes Oct. 4 at 6:35 AM
Words ... are $ANVS' actions! That's all investors are going to get. They are being conned, IMO. Promises and innuendos of "partnerships, grants, licensing deals and buy-outs that she likes to focus on in retail investor-facing communications, but nothing ever materializes other than more dilution and warrants." These events are highly unlikely to happen because Dr. Maccecchini's trial results are flukes. She knows it and she exploits this, IMO. My opinion is based on working one-on-one with her and some of her team members. Protect your savings because your "investment" in her is not going to help bring a cure. It is NOT going to help your loved one. Not all Annovis Bio investors made their decision based on hopes for profit. I know some people did so for loves ones affected by dementia or in the memories of friends and family who previously were affected by these horrible diseases. These are my notes for 24 hour caregiving: $25/hour x 24 hours/day x 365 days/year = $219,000 $35/hour x 24 hours/day x 365 days/year = $306,600 $45/hour x 24 hours/day x 365 days/year = $394,200 $75/hour x 24 hours/day x 365 days/year = $657,000 Given these figure some investors may come to the "practical" conclusion that investing in a company that could bring about a cure make sense for the greater good. Unfortunately, this is a complete fallacy. #CFODive #MauraWebberSadovi #StatNews #AdamFeuerstein #StephenSedgwickCNBC #ENDALZ #FDA_Drug_Info #SEC ⚠️➡️ Note: If you were an investor with loss from ANVS back in 2021, please consider legal action as the two previous lawsuits were dismissed w/o prejudice, thus the law allows refiling. IMO, there IS information that was not previously available that would allow 2021 investors to prevail in a Class Action suit. This is ONLY possible by acting now because the 2021 Class Period's Statute of Limitations is quickly approaching. Source of attached image: https://www.reddit.com/r/Annovis/comments/1ihtbtn/anvs_annovis_bio_inc_announces_closing_of_21/ This company is hurting families and investors with the information/propaganda that they have been putting out, such as "interviews" titled "The FDA just gave the green light to cure Alzheimers!" ... https://www.youtube.com/watch?v=CWyo6p95oPU
1 · Reply
BayTraderZ
BayTraderZ Oct. 3 at 10:39 PM
$ANVS How anyone could claim they have: been invested here for 3 years, are a good judge of character, have listened to Maria speak, and are still bullish is beyond comedy..
0 · Reply
ReturnOfEsquire
ReturnOfEsquire Oct. 3 at 3:14 PM
$ANVS Actions speak louder than words. We have that saying for a reason. We only know about Maria what she allows us to know...think about it.
0 · Reply
Hankjessie
Hankjessie Oct. 3 at 1:58 PM
$ANVS the stock is and has always been a lottery ticket. Plain and simple.
0 · Reply
ForestFoxes
ForestFoxes Oct. 3 at 4:04 AM
The largest known scam against JPMorgan Chase was related to its 2021 acquisition of the startup Frank by founder Charlie Javice, who defrauded the bank of $175 million by inflating the company's customer base. $ANVS's CEO, Dr. Maccecchini told me that she needed $200M to $250M and that she was 900% certain that her drug worked. The quote, "And there were definitely times where I painted a rosier picture than things truly were" is from Charlie Javice, not Dr. Maccecchini. However, the quote is not only fitting ... it would be applicable for nearly every webinar, interview, and data release for general consumption for Retail investors. This is based on my direct work with Dr. Maccecchini and the hundreds of communications with have traded through the years ... including, a specific period of time when she obtained a signed agreement from me in order "to help her" because I needed to see her "data".
0 · Reply
ForestFoxes
ForestFoxes Oct. 3 at 3:55 AM
$ANVS "I need millions ..."
0 · Reply
ForestFoxes
ForestFoxes Oct. 3 at 3:54 AM
I trust $ANVS's SAB infinitely ♾️ more than the CEO. Are any members of the SAB willing to state that buntanetap works remotely as much as the CEO does?
0 · Reply
ForestFoxes
ForestFoxes Oct. 3 at 3:48 AM
$ANVS comparative ... Annovis Bio does NOT employ ANY MDs on their staff. Apart from Jeffrey Cummings*, MD, who serves on their Scientific Advisory Board, it is my opinion that Dr. Maccecchini alone dictates the direction of this company and what investors are bottle 🍼 fed with her assortment of post hoc data, changed endpoints, and other clinical failures that she spins as successful. What she issues in her communication to investors and the general public are misrepresentations, IMO. In contrast, other companies boast a significant number of MDs on their advisory teams. They also are NOT on their 5th CFO 🤯🚩🚩🚩🚩🚩 For example, Cognition Therapeutics $CGTX has an entire Medical Advisors team made up of MDs, while $AVXL has 13 Scientific Advisors, most of whom are MDs (according to my last count). No other CEO consistently pumps her data as much as Maria. She claims that her "drug appears more promising than any Alzheimer's drug currently available or in development." is complete hog🐽was. I have not been able to find anyone in the industry who can corroborate that assertion! Annovis Bio investors should try themselves and speak to professionals instead of continuing to be bottle fed by Annovis Bio's spun PR, disingenuous webinars, and corporation presentations (several of which I have either drafted, been involved with, and/or provided feedback which Dr. Maccecchini accepted and made changes accordingly).
1 · Reply
ForestFoxes
ForestFoxes Oct. 3 at 3:33 AM
The Dunning–Kruger effect makes every bullish $ANVS investor an expert. It means that investors have such strong bias that they have bowed to Dr. Maccecchini's public statement that that her, "drug looks more promising than any Alzheimer drug on the market or in development". She doesn't even need any MDs because she is smarter than all of them! She's smarter than everyone!!!
0 · Reply
ReturnOfEsquire
ReturnOfEsquire Oct. 3 at 2:37 AM
1 · Reply
Latest News on ANVS
Annovis Appoints Mark Guerin as Chief Financial Officer

Sep 25, 2025, 7:30 AM EDT - 9 days ago

Annovis Appoints Mark Guerin as Chief Financial Officer


Annovis Completes Full Patent Transfer to Crystal Buntanetap

Aug 7, 2025, 8:00 AM EDT - 2 months ago

Annovis Completes Full Patent Transfer to Crystal Buntanetap


Annovis to Attend the AAIC 2025 with Four Poster Presentations

Jun 26, 2025, 8:00 AM EDT - 3 months ago

Annovis to Attend the AAIC 2025 with Four Poster Presentations


Annovis to Host Webinar and Live Q&A on June 24, 2025

Jun 5, 2025, 8:00 AM EDT - 4 months ago

Annovis to Host Webinar and Live Q&A on June 24, 2025


Annovis Bio Appoints Hui Liu as Director of Biostatistics

Apr 29, 2025, 8:00 AM EDT - 5 months ago

Annovis Bio Appoints Hui Liu as Director of Biostatistics


Annovis to Host Patients' Live Forum on February 27, 2025

Feb 19, 2025, 8:30 AM EST - 8 months ago

Annovis to Host Patients' Live Forum on February 27, 2025


Annovis Bio, Inc. Announces Proposed Public Offering

Jan 31, 2025, 8:14 PM EST - 8 months ago

Annovis Bio, Inc. Announces Proposed Public Offering


/C O R R E C T I O N -- Today's Marketplace/

Dec 4, 2024, 2:21 PM EST - 10 months ago

/C O R R E C T I O N -- Today's Marketplace/


Annovis to Host Year-End Investor Webcast on December 11, 2024

Nov 25, 2024, 8:00 AM EST - 11 months ago

Annovis to Host Year-End Investor Webcast on December 11, 2024


Annovis stock more than doubled on Tuesday: what happened?

Jul 2, 2024, 4:13 PM EDT - 1 year ago

Annovis stock more than doubled on Tuesday: what happened?


Annovis Announces New Publication in a Peer-Reviewed Journal

May 21, 2024, 7:30 AM EDT - 1 year ago

Annovis Announces New Publication in a Peer-Reviewed Journal


ForestFoxes
ForestFoxes Oct. 4 at 6:35 AM
Words ... are $ANVS' actions! That's all investors are going to get. They are being conned, IMO. Promises and innuendos of "partnerships, grants, licensing deals and buy-outs that she likes to focus on in retail investor-facing communications, but nothing ever materializes other than more dilution and warrants." These events are highly unlikely to happen because Dr. Maccecchini's trial results are flukes. She knows it and she exploits this, IMO. My opinion is based on working one-on-one with her and some of her team members. Protect your savings because your "investment" in her is not going to help bring a cure. It is NOT going to help your loved one. Not all Annovis Bio investors made their decision based on hopes for profit. I know some people did so for loves ones affected by dementia or in the memories of friends and family who previously were affected by these horrible diseases. These are my notes for 24 hour caregiving: $25/hour x 24 hours/day x 365 days/year = $219,000 $35/hour x 24 hours/day x 365 days/year = $306,600 $45/hour x 24 hours/day x 365 days/year = $394,200 $75/hour x 24 hours/day x 365 days/year = $657,000 Given these figure some investors may come to the "practical" conclusion that investing in a company that could bring about a cure make sense for the greater good. Unfortunately, this is a complete fallacy. #CFODive #MauraWebberSadovi #StatNews #AdamFeuerstein #StephenSedgwickCNBC #ENDALZ #FDA_Drug_Info #SEC ⚠️➡️ Note: If you were an investor with loss from ANVS back in 2021, please consider legal action as the two previous lawsuits were dismissed w/o prejudice, thus the law allows refiling. IMO, there IS information that was not previously available that would allow 2021 investors to prevail in a Class Action suit. This is ONLY possible by acting now because the 2021 Class Period's Statute of Limitations is quickly approaching. Source of attached image: https://www.reddit.com/r/Annovis/comments/1ihtbtn/anvs_annovis_bio_inc_announces_closing_of_21/ This company is hurting families and investors with the information/propaganda that they have been putting out, such as "interviews" titled "The FDA just gave the green light to cure Alzheimers!" ... https://www.youtube.com/watch?v=CWyo6p95oPU
1 · Reply
BayTraderZ
BayTraderZ Oct. 3 at 10:39 PM
$ANVS How anyone could claim they have: been invested here for 3 years, are a good judge of character, have listened to Maria speak, and are still bullish is beyond comedy..
0 · Reply
ReturnOfEsquire
ReturnOfEsquire Oct. 3 at 3:14 PM
$ANVS Actions speak louder than words. We have that saying for a reason. We only know about Maria what she allows us to know...think about it.
0 · Reply
Hankjessie
Hankjessie Oct. 3 at 1:58 PM
$ANVS the stock is and has always been a lottery ticket. Plain and simple.
0 · Reply
ForestFoxes
ForestFoxes Oct. 3 at 4:04 AM
The largest known scam against JPMorgan Chase was related to its 2021 acquisition of the startup Frank by founder Charlie Javice, who defrauded the bank of $175 million by inflating the company's customer base. $ANVS's CEO, Dr. Maccecchini told me that she needed $200M to $250M and that she was 900% certain that her drug worked. The quote, "And there were definitely times where I painted a rosier picture than things truly were" is from Charlie Javice, not Dr. Maccecchini. However, the quote is not only fitting ... it would be applicable for nearly every webinar, interview, and data release for general consumption for Retail investors. This is based on my direct work with Dr. Maccecchini and the hundreds of communications with have traded through the years ... including, a specific period of time when she obtained a signed agreement from me in order "to help her" because I needed to see her "data".
0 · Reply
ForestFoxes
ForestFoxes Oct. 3 at 3:55 AM
$ANVS "I need millions ..."
0 · Reply
ForestFoxes
ForestFoxes Oct. 3 at 3:54 AM
I trust $ANVS's SAB infinitely ♾️ more than the CEO. Are any members of the SAB willing to state that buntanetap works remotely as much as the CEO does?
0 · Reply
ForestFoxes
ForestFoxes Oct. 3 at 3:48 AM
$ANVS comparative ... Annovis Bio does NOT employ ANY MDs on their staff. Apart from Jeffrey Cummings*, MD, who serves on their Scientific Advisory Board, it is my opinion that Dr. Maccecchini alone dictates the direction of this company and what investors are bottle 🍼 fed with her assortment of post hoc data, changed endpoints, and other clinical failures that she spins as successful. What she issues in her communication to investors and the general public are misrepresentations, IMO. In contrast, other companies boast a significant number of MDs on their advisory teams. They also are NOT on their 5th CFO 🤯🚩🚩🚩🚩🚩 For example, Cognition Therapeutics $CGTX has an entire Medical Advisors team made up of MDs, while $AVXL has 13 Scientific Advisors, most of whom are MDs (according to my last count). No other CEO consistently pumps her data as much as Maria. She claims that her "drug appears more promising than any Alzheimer's drug currently available or in development." is complete hog🐽was. I have not been able to find anyone in the industry who can corroborate that assertion! Annovis Bio investors should try themselves and speak to professionals instead of continuing to be bottle fed by Annovis Bio's spun PR, disingenuous webinars, and corporation presentations (several of which I have either drafted, been involved with, and/or provided feedback which Dr. Maccecchini accepted and made changes accordingly).
1 · Reply
ForestFoxes
ForestFoxes Oct. 3 at 3:33 AM
The Dunning–Kruger effect makes every bullish $ANVS investor an expert. It means that investors have such strong bias that they have bowed to Dr. Maccecchini's public statement that that her, "drug looks more promising than any Alzheimer drug on the market or in development". She doesn't even need any MDs because she is smarter than all of them! She's smarter than everyone!!!
0 · Reply
ReturnOfEsquire
ReturnOfEsquire Oct. 3 at 2:37 AM
1 · Reply
justateacher
justateacher Oct. 2 at 6:55 PM
$ANVS others on this board can think and say what they want. This board is full of bears with or without personal grudges even. After 30 years teaching school and 2 masters degrees I still consider myself a rather sharp judge of character, as trust me folks….After public education for 30 years, I HAVE SEEN IT ALL! I’ve listened to Maria many many times virtually, enough said for me! Anyhow I know what I’m doing on this drug…. I’ve been long for over 2 years , could be 3 now, and still am! $ANVS
1 · Reply
CalculatedSwing
CalculatedSwing Oct. 1 at 4:02 PM
$BIVI 🚀 $BIVI heating up ahead of Oct 8 investor webinar—analysts flash Strong Buy with $16 PT from $1.90! Neuro pipeline crushing it on Alzheimer's & Parkinson's breakthroughs. Newbies, this is prime time to go all in for massive gains! 🌕 Tagging the neuro squad: $SAVA $ANVS $INMB $PRTA #Biotech #Neuro #AllIn
0 · Reply
highnihilism
highnihilism Oct. 1 at 12:28 PM
$BWAY Brainsway Trades: 2 | Total $: 365 | 0.12 × 90-Day Avg $: 3.1 K | Call $: 365 | Put $: 0 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: – $IAI U.S. Broker-Dealers & Securities Exchanges ETF Trades: 1 | Total $: 360 | 0.04 × 90-Day Avg $: 10 K | Call $: 360 | Put $: 0 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: – $HRTX Heron Therapeutics Trades: 5 | Total $: 359 | 0.02 × 90-Day Avg $: 15.6 K | Call $: 359 | Put $: 0 | Single-Leg: 93% | Multi-Leg: 7% | Contingent: – $ANVS Annovis Bio Trades: 17 | Total $: 558 | 0.07 × 90-Day Avg $: 8.4 K | Call $: 358 | Put $: 200 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: –
0 · Reply
NolAsrtormZ
NolAsrtormZ Oct. 1 at 12:04 AM
$ANVS @ForestFoxes ya keeping eye on $GRI for ipf data?
0 · Reply
G37X
G37X Sep. 30 at 9:16 PM
$OPEN this is how it’s done Maria @MaccM $ANVS Time you made good on your promises!
2 · Reply
RoyalPurp
RoyalPurp Sep. 30 at 9:02 PM
$ANVS I don’t know what is going on with this chat, but I hope for success for the patients and if my investment benefits them, and latterly myself, then keep going with the trials and hope for some great results.
0 · Reply
ImATraderBro
ImATraderBro Sep. 30 at 7:47 PM
$ANVS for a scalp enjoying the shorts pennys
0 · Reply
ForestFoxes
ForestFoxes Sep. 30 at 5:18 PM
Sadly, $ANVS does have pumpers who ONLY care about this company's stock price and NOT the fact that the drug has <1% of actually providing ANY benefit for patients. I really didn't want to believe this. https://www.youtube.com/shorts/VVslughgJKo I thought Dr. Maccecchini's vision was what she publicly has been stating it was all this years. It is NOT. She's sent me emails thanking me for understanding her technology, her former CFO has thanked me for supporting the company, she has shared her data with me that none of you have seen unless you too have signed an NDA, and she's emailed me (which I've shared with you the day BEFORE the NDA was signed Dr. Maccecchini saying that "In order to get there, I need what you write". Once in the company, Dr. Maccecchini constantly tells me to slow down. Yet, before I enter into the company she emails me for years with complaints about her staff, non-performance executives who needed to be forward facing but weren't effective, bad PR people, and on and on. I can share all of these emails as they were during the period of time in which I was ONLY a Retail investor with NOT inside information (at least that I was aware of ... Dr. Maccecchini is very sloppy with her emails and has very poor corporate hygienes). I don't care about shareholders opinion. They can have whatever opinion they have. I thoroughly understand confirmation bias. What I do care about is that Dr. Maccecchini IS WILLING and HAS tried to lure patients and their families into buying her stock. She did this during her webinar back in Feb. 2025 during her "Annovis Patients' Live Forum: Your Questions Answered (February 27, 2025)" https://www.youtube.com/watch?v=W-qYg0AL-8s&t=13s #CFODive #MauraWebberSadovi #StatNews #AdamFeuerstein #StephenSedgwickCNBC #ENDALZ #FDA_Drug_Info #NIH #NIA #SEC
1 · Reply
LeftyT
LeftyT Sep. 30 at 3:04 PM
$ANVS The analyst at Canaccord Genuity obviously doesn't listen to bearish posters here.... nor do I. GLTA longs!!!
0 · Reply
Veni_Vidi_Vici
Veni_Vidi_Vici Sep. 30 at 12:09 PM
$ANVS 81 locations with 58 recruiting https://clinicaltrials.gov/study/NCT06709014
0 · Reply
Veni_Vidi_Vici
Veni_Vidi_Vici Sep. 29 at 7:00 PM
$ANVS 2025 NIH Alzheimer’s Disease and Related Dementias Research Progress Report: Advances and Achievements https://www.nia.nih.gov/about/2025-nih-dementia-research-progress-report
3 · Reply
Veni_Vidi_Vici
Veni_Vidi_Vici Sep. 29 at 6:56 PM
$ANVS I am no expert. Do your own due diligence. Understand the risks before investing in a clinical stage biotech. Annovis Followers on Stocktwits = 9,446
4 · Reply